GSK delivers strong Q2 performance with underlying sales growth* of 5%, increased pipeline visibility and dividend of 16p, up 7%
Issued: Tuesday 26 July 2011, London, UK
Full details of GSK's results for the second quarter of 2011 can be found in the Investors section of GSK.com.
Q2 2011 results announcement (PDF)
GlaxoSmithKline enquiries:
UK Media enquiries: |
David Mawdsley |
(020) 8047 5502 |
|
Stephen Rea |
(020) 8047 5502 |
|
Sarah Spencer |
(020) 8047 5502 |
Janet Morgan |
(020) 8047 5502 |
|
David Daley |
(020) 8047 5502 |
|
|
|
|
US Media enquiries: |
Nancy Pekarek |
(919) 483 2839 |
|
Mary Anne Rhyne |
(919) 483 2839 |
|
Kevin Colgan |
(919) 483 2839 |
|
Jennifer Armstrong |
(919) 483 2839 |
|
|
|
European Analyst/Investor enquiries: |
Sally Ferguson |
(020) 8047 5543 |
|
Gary Davies |
(020) 8047 5503 |
|
Ziba Shamsi |
(020) 8047 3289 |
|
|
|
US Analyst/ Investor enquiries: |
Tom Curry |
(215) 751 5419 |
Jeff McLaughlin |
(215) 751 7002 |
